Evolving Advisory Committee Processes: Key Updates From ODAC
![](https://www.allucent.com/wp-content/uploads/2024/06/ODAC-Blog-1-1024x535.webp)
By Nadine Bouchard (VP, Regulatory Affairs, Head of Program Management) and Lisa Sanders, PhD (Sr. Director, Regulatory Affairs) Background To help in their decision-making, the US Food and Drug Administration (FDA) sometimes makes use of an Advisory Committee, as defined in various regulations. An Advisory Committee provides independent expert advice and makes non-binding recommendations to […]
EU Pharmaceutical Legislation Reform – Towards a Resolution
![](https://www.allucent.com/wp-content/uploads/2024/05/Operational-Excellence-Blog-11-1024x535.png)
By John McIntyre, PhD (Director, Clinical Strategy) and Sugato De, MSc (Vice President, Regulatory Strategy) Introduction In April 2023, the European Commission adopted a proposal for a new Directive1 and a new Regulation2 which revise and replace the existing general pharmaceutical legislation in the EU. The proposed change represents the largest reform of the European pharmaceutical legislation […]
Strengthen Your Regulatory Submissions Through Strategic Storyboarding
![](https://www.allucent.com/wp-content/uploads/2024/05/Storyboard-Blog-1-1024x535.webp)
By Young-Sil (Anna) Yim, Senior Director, Regulatory Affairs at Allucent Introduction A successful marketing authorization application is expected to convey the complete story of the drug in a clear, harmonized, and strategic manner. The process is rarely easy, as the authoring process requires distilling the full product development journey, starting from early activities including CMC […]
Optimizing Your Clinical Development Plan: Strategies for Biotech Success
![Winding path with Allucent brand overlay](https://www.allucent.com/wp-content/uploads/2024/05/CDP-Graphic-1-1024x535.webp)
By Sugato De (VP, Regulatory Strategy, Head of Medtech), Josh Taylor (Sr. Director, Regulatory Affairs), Lisa R. Sanders (Sr. Director, Regulatory Affairs), John McIntyre (Director, Clinical Strategy) Critical Importance of the Clinical Development Plan Imagine you walk onto a plot of land and decide it is the perfect place to build your next home. You […]
Navigating Regulatory Challenges: A Collaborative Journey to FDA Approval
![Puzzle pieces uncovering a seal of FDA approval](https://www.allucent.com/wp-content/uploads/2024/05/FDA-Case-Study-4-1024x535.webp)
Case Study Zachary Swan, PhD (Director, Regulatory Affairs) Background and Challenge Allucent was approached by a commercial-stage biopharmaceutical company focused on infectious diseases to provide writing and strategy support for their unique and complex New Drug Application (NDA) with multiple indications. The company faced a significant challenge when the FDA’s assessment deemed their initial studies in […]
Cell and Gene Therapy Advancements: Early-Stage CMC Strategies for Exosome Innovation
![](https://www.allucent.com/wp-content/uploads/2023/12/Exosomes-2-1-1-1024x535.webp)
By Marites T. Woon (Associate Director, Nonclinical), Mialy Ramaroson (Director, CMC), Jessica Lee (Principal, Global Head Cell & Gene Therapy) Welcome back to our exploration of the transformative world of exosomes in the second installment of our blog series. In our initial dive, we uncovered the intriguing potential of exosomes as dynamic messengers in intercellular […]
Exosomes: Unveiling Their Potential in Cell and Gene Therapy
By Marites T. Woon (Associate Director, Nonclinical), Mialy Ramaroson (Director, CMC), Jessica Lee (Principal, Global Head Cell & Gene Therapy), William Lee (Vice President, Regulatory Affairs), and Richard Stewart (Vice President, Nonclinical) Welcome to our three-part blog series on exosomes, the fascinating messengers of the cellular world. In this captivating exploration, we delve into the […]
Risk Assessment: Traditional and Novel Approaches to Assess and Manage Risks
Risk assessment is a complex process intended to protect human health by identifying drug-related hazards, determining dose-response relations for a product within relevant biological systems, and assessing exposure levels to characterize potential risks. These assessments may be conducted via traditional frameworks using data from in vitro and in vivo studies, as well as novel frameworks using pharmacokinetic and pharmacodynamic model-based […]
A Snapshot of Gap Analysis
When building a successful regulatory strategy, it is critical to keep the end objectives in mind and design a process that is tailored to your specific product. Planning for regulatory requirements can help you avoid non-compliant practices from the very beginning, but how do you make sure your strategy is comprehensive? The answer may be […]
3 Tips for IMPD Success
The Investigational Medicinal Product Dossier or IMPD contains summaries of information related to the quality, manufacture, and control of any IMP, along with data from non-clinical and clinical studies, including the overall benefit and risk assessment. The IMPD is a critical part of the European clinical trial application, as the clinical trial may not be […]